Stock News

Analysts See $-0.76 EPS for Summit Therapeutics plc (SMMT); Avinger (AVGR) Sellers Increased By 12.02% Their Shorts

Avinger, Inc. (NASDAQ:AVGR) Logo

Avinger Inc (NASDAQ:AVGR) had an increase of 12.02% in short interest. AVGR’s SI was 353,300 shares in May as released by FINRA. Its up 12.02% from 315,400 shares previously. With 2.64M avg volume, 0 days are for Avinger Inc (NASDAQ:AVGR)’s short sellers to cover AVGR’s short positions. The stock increased 73.54% or $0.95 during the last trading session, reaching $2.23. About 48.74 million shares traded or 2359.45% up from the average. Avinger, Inc. (NASDAQ:AVGR) has declined 98.16% since May 24, 2017 and is downtrending. It has underperformed by 109.71% the S&P500.

Analysts expect Summit Therapeutics plc (NASDAQ:SMMT) to report $-0.76 EPS on June, 13.They anticipate $0.26 EPS change or 52.00% from last quarter’s $-0.5 EPS. After having $-1.15 EPS previously, Summit Therapeutics plc’s analysts see -33.91% EPS growth. The stock decreased 1.17% or $0.16 during the last trading session, reaching $13.49. About 19,763 shares traded. Summit Therapeutics plc (NASDAQ:SMMT) has risen 4.52% since May 24, 2017 and is uptrending. It has underperformed by 7.03% the S&P500.

Avinger, Inc., a commercial-stage medical device company, designs, makes, and sells image-guided and catheter systems used by physicians to treat patients with peripheral arterial disease in the United States and Europe. The company has market cap of $10.80 million. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. It currently has negative earnings. The companyÂ’s lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients.

More important recent Avinger, Inc. (NASDAQ:AVGR) news were published by: Globenewswire.com which released: “Avinger Receives FDA Clearance of Next Generation Pantheris Device” on May 23, 2018, also Streetinsider.com published article titled: “Pre-Open Movers 05/23: (AVGR) (CARA) (TIF) Higher; (RRGB) (PFNX) (TCS) Lower (more…)”, Globenewswire.com published: “Avinger Announces First Quarter 2018 Financial Results” on May 14, 2018. More interesting news about Avinger, Inc. (NASDAQ:AVGR) was released by: Seekingalpha.com and their article: “Avinger’s (AVGR) CEO Jeff Soinski on Q1 2018 Results – Earnings Call Transcript” with publication date: May 14, 2018.

Among 3 analysts covering Avinger (NASDAQ:AVGR), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Avinger had 3 analyst reports since December 29, 2015 according to SRatingsIntel. The firm earned “Perform” rating on Wednesday, April 12 by Oppenheimer. The rating was downgraded by Canaccord Genuity to “Hold” on Tuesday, April 11. The stock of Avinger, Inc. (NASDAQ:AVGR) has “Neutral” rating given on Tuesday, December 29 by Dougherty & Company.

More recent Summit Therapeutics plc (NASDAQ:SMMT) news were published by: Globenewswire.com which released: “Summit Therapeutics plc : Notice of AGM” on May 03, 2018. Also Benzinga.com published the news titled: “Summit Therapeutics’ Upcoming Duchenne Muscular Dystrophy Data ‘A Strong Catalyst,’ Janney Says In Bullish Initiation” on May 05, 2018. Benzinga.com‘s news article titled: “Benzinga’s Top Upgrades, Downgrades For May 2, 2018” with publication date: May 02, 2018 was also an interesting one.

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. The company has market cap of $211.21 million. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI). It currently has negative earnings. The companyÂ’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease.

Among 10 analysts covering Summit Therapeutic (NASDAQ:SMMT), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Summit Therapeutic had 18 analyst reports since August 19, 2015 according to SRatingsIntel. On Wednesday, August 19 the stock rating was maintained by Oppenheimer with “Buy”. Zacks downgraded the shares of SMMT in report on Tuesday, September 1 to “Hold” rating. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, April 11. The firm earned “Outperform” rating on Wednesday, November 16 by RBC Capital Markets. The stock has “Buy” rating by SunTrust on Friday, April 13. Canaccord Genuity maintained Summit Therapeutics plc (NASDAQ:SMMT) on Tuesday, March 6 with “Buy” rating. The firm earned “Buy” rating on Friday, December 1 by H.C. Wainwright. The stock has “Buy” rating by Janney Capital on Tuesday, June 21. H.C. Wainwright initiated the stock with “Buy” rating in Friday, September 16 report. The rating was maintained by Oppenheimer with “Buy” on Thursday, June 22.

Summit Therapeutics plc (NASDAQ:SMMT) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *